Academic literature on the topic 'BRAF/RAS wild type'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'BRAF/RAS wild type.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "BRAF/RAS wild type"
Landa, Iñigo, Ian Ganly, Timothy A. Chan, Norisato Mitsutake, Michiko Matsuse, Tihana Ibrahimpasic, Ronald A. Ghossein, and James A. Fagin. "Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease." Journal of Clinical Endocrinology & Metabolism 98, no. 9 (September 1, 2013): E1562—E1566. http://dx.doi.org/10.1210/jc.2013-2383.
Full textCalegari, Maria Alessandra, Lisa Salvatore, Brunella Di Stefano, Michele Basso, Armando Orlandi, Alessandra Boccaccino, Fiorella Lombardo, et al. "Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study)." Cancers 13, no. 9 (April 27, 2021): 2098. http://dx.doi.org/10.3390/cancers13092098.
Full textMaurel, Joan, Vicente Alonso, Pilar Escudero, Carlos Fernández-Martos, Antonieta Salud, Miguel Méndez, Javier Gallego, et al. "Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti–Epidermal Growth Factor Receptor Therapy." JCO Precision Oncology, no. 3 (December 2019): 1–16. http://dx.doi.org/10.1200/po.18.00289.
Full textKotoula, Vassiliki, Elias Sozopoulos, Helen Litsiou, Galinos Fanourakis, Triantafyllia Koletsa, Gerassimos Voutsinas, Sophia Tseleni-Balafouta, Constantine S. Mitsiades, Axel Wellmann, and Nicholas Mitsiades. "Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas." Endocrine-Related Cancer 16, no. 2 (June 2009): 565–72. http://dx.doi.org/10.1677/erc-08-0101.
Full textBilgetekin, Irem, Mehmet Dogan, Cengiz Karacin, Fatma Bugdayci Basal, Ece Esin, Gokhan Ucar, Ozlem Aydin Isak, et al. "The temporal evaluation of RAS and BRAF mutation by liquid biopsy at progression after bevacizumab combinations in patients with metastatic colorectal cancer (mCRC)." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e15587-e15587. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e15587.
Full textWang, Chongkai, Jaideep Sandhu, and Marwan Fakih. "Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer." Oncologist 27, no. 2 (February 1, 2022): 104–9. http://dx.doi.org/10.1093/oncolo/oyab028.
Full textYoshino, Takayuki, Radka Obermannova, Gyorgy Bodoky, Jana Prausová, Rocio Garcia-Carbonero, Tudor-Eliade Ciuleanu, Pilar Garcia Alfonso, et al. "Are BRAF mutated metastatic colorectal cancer (mCRC) tumors more responsive to VEGFR-2 blockage? Analysis of patient outcomes by RAS/RAF mutation status in the RAISE study—A global, randomized, double-blind, phase III study." Journal of Clinical Oncology 36, no. 4_suppl (February 1, 2018): 622. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.622.
Full textConroy, Jeffrey M., Sarabjot Pabla, Marc S. Ernstoff, Igor Puzanov, Mary Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, et al. "Comprehensive immune and mutational profile of melanoma." Journal of Clinical Oncology 36, no. 5_suppl (February 10, 2018): 182. http://dx.doi.org/10.1200/jco.2018.36.5_suppl.182.
Full textRomano, David, Lucía García-Gutiérrez, Nourhan Aboud, David J. Duffy, Keith T. Flaherty, Dennie T. Frederick, Walter Kolch, and David Matallanas. "Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma." Life Science Alliance 5, no. 10 (August 29, 2022): e202201445. http://dx.doi.org/10.26508/lsa.202201445.
Full textDillon, Martha, Antonio Lopez, Edward Lin, Dominic Sales, Ron Perets, and Pooja Jain. "Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers." Cancers 13, no. 20 (October 10, 2021): 5059. http://dx.doi.org/10.3390/cancers13205059.
Full textDissertations / Theses on the topic "BRAF/RAS wild type"
Rebecca, Vito William. "Potential Targeted Therapeutic Strategies for Overcoming Resistance in BRAF Wild Type Melanoma." Scholar Commons, 2014. http://scholarcommons.usf.edu/etd/5112.
Full textMoka, Nagaishwarya, Kelley cross, Marianne Brannon, Janet Lightner, Megan Dycus, William Stone, Victoria Palau, and Koyamangalath Krishnan. "Delta-tocotrienol and simvastatin induces differential cytotoxicity and synergy in BRAF wild-type SK-MEL-2 and mutant BRAF SK-MEL-28 melanoma cancer cells." Digital Commons @ East Tennessee State University, 2018. https://dc.etsu.edu/asrf/2018/schedule/215.
Full textFerguson, Robert. "Wild-type N-Ras complements mutant K-Ras in pancreatic cancer cell lines but K-Ras has a specific role in cell cycle independent regulation of G2 cyclins." Thesis, University of Liverpool, 2015. http://livrepository.liverpool.ac.uk/2032380/.
Full textSree, Kumar Shalini. "Biomarkers of resistance to anti-EGFR in wild type KRAS/BRAF colorectal cancer cell lines." Thesis, 2015. http://hdl.handle.net/2440/104679.
Full textThesis (Ph.D.) (Research by Publication) -- University of Adelaide, School of Medical Sciences, 2015.
Weyandt, Jamie Dawn. "Investigatiing the Role of the Wild-Type Ras Isoforms in KRas-driven Cancer." Diss., 2015. http://hdl.handle.net/10161/11392.
Full textThe RAS family is a group of small GTPases that can become constitutively activated by point mutations that are found in about 30% of all cancer patients. There are three well-characterized RAS family members: HRAS, NRAS, and KRAS, the latter of which is alternatively spliced at the C-terminus into KRAS4A and KRAS4B. The RAS proteins are all nearly identical at their N-termini and core effector binding domains, but have divergent C-terminal membrane-binding regions that impart different subcellular localization and subtle differences in signaling. Although the role of constitutively activated oncogenic RAS has been well established to play a role in cancer, recent work has suggested that wild-type RAS signaling may also be important in tumorigenesis. Wild-type RAS proteins have been shown to be activated in the presence of oncogenic KRAS. However, the consequences of this activation are context-dependent, as signaling through the wild-type RAS proteins has been shown to both suppress neoplastic growth and promote tumorigenesis under different circumstances.
I sought to investigate the role of the wild-type RAS proteins in two clinically –relevant models of cancer: pancreatic, the type of cancer most frequently associated with KRAS mutations, and lung cancer, the cancer in which KRAS mutations affect the highest number of patients. First, I tested whether a loss of wild type Hras altered tumorigenesis in a mouse model of pancreatic cancer driven by oncogenic Kras. Hras homozygous null mice (Hras-/- ) exhibited more precancerous lesions of the pancreas as well as more off-target skin papillomas compared to their wild type counterparts, indicating that Hras suppresses early Kras-driven pancreatic tumorigenesis. Loss of Hras also reduced the survival of mice engineered to develop aggressive pancreatic cancer by the additional disruption of one allele of the tumor suppressor p53 (Trp53R172H/+). However, this survival advantage was lost when both alleles of Trp53 were mutated, suggesting that wild-type HRas inhibits tumorigenesis in a p53-dependant manner.
Next, I investigated the role that wild-type Hras and Nras play in a chemical carcinogen-induced model of lung cancer. In mice treated with urethane, a carcinogen that induces Kras-mutation positive lung lesions, Hras-/ mice once again developed more tumors than wild-type mice. Interestingly, however, this effect was not observed in mice lacking wild-type Nras. Mice lacking both Hras and Nras alleles developed approximately the same number of tumors as Hras-/- mice, thus the additional loss of Nras does not appear to enhance the tumor-promoting effects of loss of Hras. In summary, signaling through wild-type Hras, but not Nras, suppresses tumorigenesis in a carcinogen-induced model of lung cancer.
The tumor-suppressive effects of wild-type Ras signaling were traced to the earliest stages of pancreatic tumorigenesis, suggesting that wild-type Ras signaling may suppress tumorigenesis as early as the time of initiation. These findings suggest that differences in expression of the wild-type Ras isoforms could potentially play a role in an individual’s predisposition for developing cancer upon oncogenic insult.
Dissertation
Chun-ILi and 李俊毅. "The effect of miR-146a and target gene vimentin on tumorigenesis of esophageal squamous cell carcinoma cell lines overexpressing wild-type K-Ras gene." Thesis, 2018. http://ndltd.ncl.edu.tw/handle/b64k4e.
Full textBook chapters on the topic "BRAF/RAS wild type"
Chandra, Sunandana, Grant McArthur, and Jeffrey Sosman. "Molecularly Targeted Therapy for Patients with BRAF Wild-Type Melanoma." In Cutaneous Melanoma, 1–22. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-46029-1_55-1.
Full textChandra, Sunandana, Grant A. McArthur, and Jeffrey Sosman. "Molecularly Targeted Therapy for Patients with BRAF Wild-Type Melanoma." In Cutaneous Melanoma, 1087–108. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-05070-2_55.
Full textWittinghofer, Alfred, Sybille M. Franken, Axel J. Scheidig, Hans Rensland, Alfred Lautwein, Emil F. Pai, and Roger S. Goody. "Three-Dimensional Structure and Properties of Wild-Type and Mutant H-ras-Encoded p21." In Ciba Foundation Symposium 176 - The GTPase Superfamily, 6–27. Chichester, UK: John Wiley & Sons, Ltd., 2007. http://dx.doi.org/10.1002/9780470514450.ch2.
Full textKataoka, Keiko. "Fermented Brown Rice as a Functional Food." In Rice [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.98840.
Full textBabu, Geethu, R. Rejnish Ravi Kumar, Malu Rafi, Lekha M. Nair, Zuzaki Sharafuddin, John Mathew, Nijo Jose, and Cessal Thommachan Kainickal. "Systemic Therapy in Thyroid Cancer." In Thyroid Cancer - The Road From Genes to Successful Treatment [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.106462.
Full textJinga, Dan-Corneliu, and Maria-Ruxandra Jinga. "Immunotherapy of Metastatic Melanoma." In Melanoma - Standard of Care, Challenges, and Updates in Clinical Research [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.105585.
Full textTizro, Parastou, Rami Abdulbaki, Anita Aggarwal, Aaron Auerbach, and Victor E. Nava. "Splenic B-Cell Lymphoma/Leukemia, Unclassifiable." In Lymphoma [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.101418.
Full textConference papers on the topic "BRAF/RAS wild type"
Poulikakos, Poulikos I., Chao Zhang, Eric W. Joseph, Yogindra Persaud, Christine A. Pratilas, Gideon Bollag, David B. Solit, Kevan M. Shokat, and Neal Rosen. "Abstract LB-190: RAF inhibitors transactivate RAF dimers and ERK signaling in a wild-type BRAF-dependent manner." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-lb-190.
Full textCapparelli, Claudia, Nadège Gaborit, Yosef Yarden, and Andrew Aplin. "Abstract C44: Targeting neuregulin1-ErbB3 signaling in wild-type BRAF/NRAS melanoma." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-c44.
Full textPopovici, Vlad, Eva Budinska, Sabine Tejpar, Arnaud Roth, Fredrik Bosman, Scott Weinrich, Graeme Hodgson, and Mauro Delorenzi. "Abstract 4722: A BRAF-mutated gene expression signature identifies BRAF wild type colon cancer patients with poor prognosis." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-4722.
Full textMing, Zizhen, Su Yin Lim, Richard F. Kefford, and Helen Rizos. "Abstract 765: Multiple signalling pathways are active in BRAF/NRAS wild type melanomas." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-765.
Full textZhang, Yanping, Guangyong Peng, and Eddy C. Hsueh. "Abstract 375: Combination of MEK and PI3K inhibition in BRAF wild-type and mutant melanoma." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-375.
Full textBanjin, Maja, Amina Jalovčić, and Velda Smajlbegović. "CILJANA TERAPIJA I METASTATSKI MELANOM." In Okrugli sto s međunarodnim učešćem "Melanom". Akademija nauka i umjetnosti Bosne i Hercegovine, 2018. http://dx.doi.org/10.5644/pi2019.180.02.
Full textRosenbaum, Sheera, Claudia Capparelli, Lisa D. Berman-Booty, Nadège Gaborit, Tingting Zhan, Michael A. Davies, Yulius Y. Setiady, Yosef Yarden, and Andrew E. Aplin. "Abstract A52: Extracellular matrix regulation of ErbB3 in a subset of wild-type BRAF/NRAS melanoma." In Abstracts: AACR Special Conference: Targeting the PI3K-mTOR Network in Cancer; September 14-17, 2014; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-8514.pi3k14-a52.
Full textFragomeni, Roberto A. Salas, Hye-Won Chung, Sharon Shacham, Michael Kauffman, and James C. Cusack. "Abstract 1914: Potent anticancer activity against both BRAF-mutant and BRAF wild-type melanoma cell lines using a novel CRM1 nuclear export inhibitor." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-1914.
Full textHaendler, Bernard, Kathy A. Gelato, Laura Schöckel, Tatsuo Sugawara, Pascale Lejeune, Heidrun Ellinger-Ziegelbauer, Amaury E. Fernandez-Montalvan, et al. "Abstract 4703: The BET inhibitor BAY 1238097 shows efficacy in BRAF wild-type and mutant melanoma models." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-4703.
Full textEssner, Richard, Ke Wei Gong, David Kaufman, Hsiaowang Chen, Charles Ginther, Judy Dering, Erika von Euw, Bartosz Chmielowski, Richard Finn, and Dennis Slamon. "Abstract A26: Protein phosphatase 4 (PP4) as a potential therapeutic target gene for BRAF wild type melanoma." In Abstracts: AACR Special Conference on Advances in Melanoma: From Biology to Therapy; September 20-23, 2014; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.mel2014-a26.
Full text